Shield Therapeutics plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| STX.L | MDP.TO | RX.V | IRWD | CPH.TO | SFZN.SW | |
|---|---|---|---|---|---|---|
| Market cap | 36.52M | 158.39M | 192.63M | 622.95M | 331.16M | 3.27B |
| P/E (TTM) | — | — | 20.2 | 4.9 | 8.5 | 19.1 |
| Forward P/E | 4.5 | -252.0 | 30.6 | 2.5 | — | 15.9 |
| Price/book | -2.8 | 2.4 | 4.2 | -3.9 | 1.7 | 3.3 |
| Dividend yield | — | — | 1.28% | — | — | 0.53% |
| 1-year change | −55.80% | +90.19% | +59.24% | +69.90% | −12.08% | +0.20% |
| Today | −1.45% | +1.41% | +1.78% | +7.71% | −0.31% | −0.27% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All STX.L news ›Shield Therapeutics Drops 2026 Profit Target
Discover our top-rated, regulated brokers. Compare platforms, fees and features, and explore the latest broker offers. Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of…
Shield Therapeutics loses profitability target as Medicaid pressures offset prescription growth
Shield Therapeutics PLC (AIM:STX, OTCQB:SHIEF), the pharmaceutical company behind iron deficiency treatment Accrufer, has abandoned its target of operating profitability in 2026 after higher US commercial costs. Peel Hunt retained its…
REG - Shield Therapeutics - Q3 2026 Trading Update
("Shield" or the "Company" or the "Group") Q3 commercial sales growth continues as Shield enters new phase of value creation with full US control of ACCRUFeR® Increase in net revenue with per prescription increase to $217 London, UK, 3…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- asktraders.com1
- proactiveinvestors.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.